Evidence map›Paper›PMID 36519322›Full record

ArticleHaematologica2023

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib.

Alexander P Bye, Neline Kriek, Tanya Sage, Suzannah J Rawlings, Catherine Prodger, Murali Kesavan, Charlotte Lees, Stephen Booth, Louise G Cowen, Kirsty Shefferd and 3 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Alexander P ByeMolecular and Clinical Sciences Research Institute, St George's University, Cranmer Terrace, London, United Kingdom; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX. a.bye@sgul.ac.uk.
Neline KriekInstitute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX.
Tanya SageInstitute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX.
Suzannah J RawlingsInstitute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading,.
Catherine ProdgerDepartment of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.
Murali KesavanDepartment of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.
Charlotte LeesDepartment of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.
Stephen BoothDepartment of Clinical Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, RG1 5AN.
Louise G CowenHaematology Late Phase Clinical Trial Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.
Kirsty ShefferdHaematology Late Phase Clinical Trial Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.
Michael J DesboroughDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.
Jonathan M GibbinsInstitute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX.
Toby A EyreDepartment of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford,.
University of Reading · GBOxford University Hospitals NHS Trust · GBUniversity of Oxford · GBChurchill Hospital · GBRoyal Berkshire NHS Foundation Trust · GBSt George's, University of London · GB

Funding

British Heart Foundation RG/20/7/34866
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellPyrazinesAdenineBenzamidesHumansPiperidinesProtein Kinase InhibitorsPyrazolesacalabrutinibAdenineBenzamidesibrutinibPiperidinespirtobrutinibProtein Kinase InhibitorsPyrazinesPyrazoles

Identifiers

PMID36519322
PMCPMC10153540
OpenAlexW4311583105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.